Pharvaris (NASDAQ:PHVS) Director Sells $1,989,225.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Elisabeth Bjork sold 52,500 shares of Pharvaris stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $37.89, for a total transaction of $1,989,225.00. Following the sale, the director owned 15,167 shares of the company’s stock, valued at approximately $574,677.63. This represents a 77.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pharvaris Stock Performance

Pharvaris stock opened at $33.07 on Thursday. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -10.84 and a beta of -2.33. The company’s 50 day simple moving average is $35.36 and its 200-day simple moving average is $31.93. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities analysts expect that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Hedge Funds Weigh In On Pharvaris

Large investors have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new position in Pharvaris during the second quarter worth approximately $41,000. CoreCap Advisors LLC acquired a new stake in shares of Pharvaris in the second quarter valued at approximately $93,000. Amundi grew its position in shares of Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company’s stock worth $874,000 after acquiring an additional 3,312 shares during the last quarter. Sofinnova Investments Inc. grew its position in shares of Pharvaris by 0.7% during the fourth quarter. Sofinnova Investments Inc. now owns 745,169 shares of the company’s stock worth $20,678,000 after acquiring an additional 5,293 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Pharvaris in the 2nd quarter valued at $196,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Guggenheim boosted their price target on shares of Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Wells Fargo & Company increased their target price on shares of Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Finally, Wedbush raised their price target on shares of Pharvaris from $42.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.